Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoOVIV Vaccine in Patients With Ovarian Cancer After Surgery
NCT07676890Phase 1Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NeoOVIV in ovarian cancer, sponsored by West China Hospital of Sichuan University. Primary endpoint: Incidence of Treatment-Emergent Adverse Events Assessed by CTCAE Version 5.0 at 18 months. Started Sep 2026; status: recruiting.
02
Drugs
NeoOVIV
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07676890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07676890.